Magnet Biomedicine & Eli Lilly Partner to Develop Molecular Glue Medicines

Molecular glue company, Magnet Biomedicine has entered into a collaboration and license agreement with Eli Lilly to discover, develop, and commercialize molecular glue therapeutics, with a focus on oncology applications. The collaboration will utilize Magnet’s TrueGlue™ discovery platform to identify molecular glues that induce protein proximity and cooperativity. The companies are to target unmet medical needs to drive breakthrough therapies in cancer and other challenging diseases.

Magnet will receive up to USD 40 mn in upfront payments, including an equity investment, with potential milestones surpassing USD 1.25 bn upon achieving development, regulatory, and commercial milestones, with tiered royalties on global net sales.

Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design, announced a collaboration and license agreement with Eli Lilly and Company to discover, develop, and commercialize molecular glue therapeutics in oncology. The collaboration will leverage Magnet’s TrueGlue™ discovery platform to identify molecular glues capable of inducing protein proximity and cooperativity, enabling novel mechanisms of action to address difficult-to-drug targets spanning multiple diseases with unmet medical need.

"This collaboration supports our differentiated approach and efforts to reimagine what’s achievable through the next generation of molecular glues to drive breakthrough therapies,” said Brian Safina, Ph.D., CEO of Magnet. "Lilly’s commitment to innovation and deep expertise in bringing transformative medicines to patients make it an ideal partner for Magnet as we harness the untapped potential of molecular glues.”

Under the terms of the agreement, Magnet will receive upfront, near-term payments and an equity investment of up to $40 million. Magnet is also eligible to receive a total of more than $1.25 billion in milestones upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales.

For more, please find the original story source here.